The estimated Net Worth of Jean George is at least $66.6 Million dollars as of 26 June 2019. Ms. George owns over 37,500 units of Calithera Biosciences Inc stock worth over $2,063 and over the last 20 years she sold CALA stock worth over $66,473,851. In addition, she makes $95,472 as Independent Director at Calithera Biosciences Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Ms. George CALA stock SEC Form 4 insiders trading
Jean has made over 12 trades of the Calithera Biosciences Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently she exercised 37,500 units of CALA stock worth $988,125 on 26 June 2019.
The largest trade she's ever made was buying 1,277,373 units of Calithera Biosciences Inc stock on 20 June 2005 worth over $7,000,004. On average, Jean trades about 107,587 units every 146 days since 2004. As of 26 June 2019 she still owns at least 41,250 units of Calithera Biosciences Inc stock.
You can see the complete history of Ms. George stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jean George biography
Jean M. George serves as Independent Director of the Company. Ms. George has served as a member of our board of directors since September 2012. Since February 2002, she has been a General Partner at Advanced Technology Ventures, a venture capital fund. Since April 2013, Ms. George has been a General Partner at Lightstone Ventures, a venture capital fund. From September 1998 to January 2002, Ms. George served as director of BancBoston Ventures, a venture capital fund. Ms. George currently serves as a member of the board of directors of Acceleron Pharma, Inc. and Catabasis Pharmaceuticals, Inc. Ms. George holds a B.S. in Biology from the University of Maine and an M.B.A. from Simmons College Graduate School of Management.
What is the salary of Jean George?
As the Independent Director of Calithera Biosciences Inc, the total compensation of Jean George at Calithera Biosciences Inc is $95,472. There are 9 executives at Calithera Biosciences Inc getting paid more, with Susan Molineaux having the highest compensation of $2,209,840.
How old is Jean George?
Jean George is 62, she's been the Independent Director of Calithera Biosciences Inc since 2012. There are 7 older and 15 younger executives at Calithera Biosciences Inc. The oldest executive at Calithera Biosciences Inc is H. Ward Wolff, 71, who is the Independent Director.
What's Jean George's mailing address?
Jean's mailing address filed with the SEC is 1 Kendall Square B14202, Cambridge, MA 02139, USA.
Insiders trading at Calithera Biosciences Inc
Over the last 10 years, insiders at Calithera Biosciences Inc have traded over $23,150,153 worth of Calithera Biosciences Inc stock and bought 7,859,025 units worth $49,155,939 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Partners Gp, L.L.C...., and Deepika Pakianathan. On average, Calithera Biosciences Inc executives and independent directors trade stock every 43 days with the average trade being worth of $8,053. The most recent stock trade was executed by Deepika Pakianathan on 27 January 2023, trading 121,333 units of CALA stock currently worth $47,320.
What does Calithera Biosciences Inc do?
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
What does Calithera Biosciences Inc's logo look like?
Complete history of Ms. George stock trades at Acceleron Pharma Inc, Calithera Biosciences Inc, Astria Therapeutics Inc, Portola Pharmaceuticals, and Cortexyme Inc
Calithera Biosciences Inc executives and stock owners
Calithera Biosciences Inc executives and other stock owners filed with the SEC include:
-
Susan Molineaux,
President, Chief Executive Officer, Co-Founder, Director -
Sumita Ray,
Senior Vice President, Chief Compliance Officer, General Counsel -
Keith Orford,
Chief Medical Officer -
Curtis Hecht,
Chief Business Officer -
Dr. Susan M. Molineaux Ph.D.,
Founder, CEO, Pres & Director -
Christopher Molineaux,
Senior Vice President - Development -
Eric Sjogren,
Senior Vice President - Drug Discovery -
Deepa Pakianathan,
Lead Independent Director -
H. Ward Wolff,
Independent Director -
Jean George,
Independent Director -
Sunil Agarwal,
Independent Director -
Suzy Jones,
Independent Director -
Blake Wise,
Independent Director -
Jonathan Drachman,
Independent Director -
Scott Garland,
Independent Director -
Jennifer McNealey,
Vice President, Investor Relations and Strategy -
Francesco Parlati,
Vice President - Research -
Stephanie Wong,
Vice President - Finance, Secretary -
Dr. Allison Dillon Ph.D.,
Sr. VP of Commercial & Portfolio Strategy -
Dr. Susan B. Demo Ph.D.,
Sr. VP of R&D Operations -
Matthew Gross,
Head of Bus. Devel. -
Dr. Emil T. Kuriakose M.D.,
Chief Medical Officer -
Frank Parlati,
Sr. VP of Research -
Dr. Christopher J. Molineaux Ph.D.,
Sr. VP of Devel. -
Dr. Eric B. Sjogren,
Sr. VP of Drug Discovery -
Sumita Ray J.D.,
Chief Legal & Admin. Officer -
Stephanie Wong,
CFO & Sec. -
Capital Partners Gp, L.L.C....,
-
William D. Waddill,
SENIOR VP & CFO -
Mark K Bennett,
SR. VP, RESEARCH -
Venture Partners Ix Lp Morg...,
10% owner -
Management Partners Viii, L...,
-
Technology Ventures Viii Lp...,
-
Ralph E Christoffersen,
Director -
Partners L P/Ilbiotechnolog...,
-
Pharmaceutical Co Ltd Taked...,
-
Deepika Pakianathan,
Director -
Emil Kuriakose,
CHIEF MEDICAL OFFICER